STING, SUMO In Spotlight As Takeda Showcases Oncology Progress

 
• By Ian Haydock

Japanese firm points to progress in its cancer pipeline as it looks to launch three new molecular entities in the sector by 2024 and investigates novel modalities.  

Treatment for malignant cancer cells in a human body caused by environmental carcinogens and genetics as a target aiming at the cancerous cell as an immunotherapy therapy as a 3D illustration.
Cancer Firmly In Takeda's Sights As Pipeline Progresses • Source: Shutterstock

More from Clinical Trials

More from R&D